6 results
Primary objective• To evaluate efficacy of acalabrutinib/venetoclax (AV) in terms of undetectable minimal residual disease (uMRD) response in bone marrow (BM) after 26 cycles of treatment in patients with CLL previously treated with venetoclax and…
Primary objective: To determine the efficacy of the combination of acalabrutinib and venetoclax without obinutuzumab (AV; Arm A), or with obinutuzumab (AVG; Arm B) compared with chemoimmunotherapy (fludarabine/cyclophosphamide/rituximab [FCR]/…
The aim is thereby to reduce the risk of serious infections and the need for regular CLL treatment.
Therapy:The investigational product, ACP-196, will be supplied as hardgelatin capsules for oral administration.Commercially available ibrutinib (IMBRUVICA®) will be used asthe reference therapy.Objectives: Primary Objective:To assess whether ACP-196…
The aim of the study is to improve the positioning of patients who are irradiated on the breast. Optical surface scanning will be used and the precision, patient friendliness, and process optimization are studied.
The aim of the study is to investigate the clinical feasibility of irradiation without a mask for head and neck cancer patients. Optical surface scanning will be used and the set-up accuracy, intra-fractional motion, patient friendliness, and…